Summary of Key Points Core Viewpoint - On October 17, 42 Hong Kong-listed companies conducted share buybacks, totaling 46.36 million shares and an aggregate amount of HKD 621 million [1][2]. Company-Specific Summaries - **Xiaomi Group-W**: - Repurchased 10.70 million shares for HKD 494 million, with a highest price of HKD 46.760 and a lowest price of HKD 45.900. The total buyback amount for the year reached HKD 1.537 billion [1][2]. - **Sihuan Pharmaceutical**: - Repurchased 15 million shares for HKD 21.76 million, with a highest price of HKD 1.470 and a lowest price of HKD 1.430. The total buyback amount for the year reached HKD 143.32 million [1][2]. - **Mengniu Dairy**: - Repurchased 1.20 million shares for HKD 16.97 million, with a highest price of HKD 14.250 and a lowest price of HKD 14.070. The total buyback amount for the year reached HKD 433.54 million [1][2]. - **AAC Technologies**: - Repurchased 300,000 shares for HKD 11.60 million, with a highest price of HKD 38.800 and a lowest price of HKD 38.480. The total buyback amount for the year reached HKD 84.64 million [1][2]. - **Vitasoy International**: - Repurchased 1.02 million shares for HKD 8.20 million, with a highest price of HKD 8.040 and a lowest price of HKD 8.020. The total buyback amount for the year reached HKD 27.54 million [1][2]. Overall Market Activity - The highest buyback amount on October 17 was from Xiaomi Group-W at HKD 494 million, followed by Sihuan Pharmaceutical at HKD 21.76 million. Other notable companies included Mengniu Dairy and AAC Technologies [1][2]. - In terms of share quantity, Sihuan Pharmaceutical led with 15 million shares repurchased, followed by Xiaomi Group-W with 10.70 million shares and Anton Oilfield Services with 4.49 million shares [1][2].

Group 1 - Yongtai Biologics-B (06978.HK) increased by 14.94% [1] - Hepp Pharmaceuticals-B (02142.HK) rose by 5.32% [1] - Rongchang Biologics (09995.HK) gained 5.14% [1] - Yaojie Ankang (02617.HK) saw an increase of 5.02% [1] - Cornerstone Pharmaceuticals-B (02616.HK) experienced a rise of 3.92% [1]

Core Viewpoint - Multiple companies in China conducted share buybacks on October 17, 2025, with Xiaomi Group-W leading in terms of buyback amount and quantity [1][2] Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 10.70 million shares for a total of 494 million yuan, with a year-to-date total of 27.30 million shares, representing 0.110% of its total share capital [2] - Four Seasons Pharmaceutical (00460) repurchased 15 million shares for 21.76 million yuan, with a year-to-date total of 59.60 million shares, representing 0.647% of its total share capital [2] - Mengniu Dairy (02319) repurchased 1.20 million shares for 16.97 million yuan, with a year-to-date total of 18.52 million shares, representing 0.473% of its total share capital [2] Group 2: Other Notable Buybacks - VITASOY International (00345) repurchased 1.02 million shares for 8.20 million yuan, with a year-to-date total of 566.60 million shares, representing 0.540% of its total share capital [2] - Zhongtong Express-W (02057) repurchased 445,000 shares for 8.41 million yuan, with a year-to-date total of 5.07 million shares, representing 0.630% of its total share capital [2] - Huazhong Media (00685) repurchased 500,000 shares for 50,000 yuan, with a year-to-date total of 225.60 million shares, representing 0.139% of its total share capital [2]

Core Points - The company, Heptagon Pharmaceuticals-B, repurchased 400,000 shares on October 17 at a price range of HKD 12.740 to HKD 13.100, totaling HKD 5.1349 million [2] - The stock closed at HKD 12.790 on the same day, reflecting a decline of 4.84%, with a total trading volume of HKD 74.9912 million [2] - Year-to-date, the company has conducted 52 repurchase transactions, acquiring a total of 22.793 million shares for a cumulative amount of HKD 156 million [2] Repurchase Details - On October 17, 2025, the company repurchased 40,000 shares at a maximum price of HKD 13.100 and a minimum price of HKD 12.740, with a total expenditure of HKD 513.49 thousand [2] - The repurchase activity has shown a consistent trend, with multiple transactions occurring throughout the year, indicating a strategic approach to managing share value [3] - The highest recorded repurchase price this year was HKD 15.330 on October 9, while the lowest was HKD 2.270 on January 8 [3]

Group 1 - The company, He Bo Pharmaceutical-B (02142.HK), announced a share buyback on October 17, 2023, spending HKD 5.135 million to repurchase 400,000 shares [1]

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142), announced a share buyback plan, indicating confidence in its financial position and future prospects [1] Group 1 - The company will repurchase 400,000 shares at a total cost of HKD 5.1349 million [1]

Core Viewpoint - The company, HAPO Pharmaceuticals-B (02142), announced a share buyback plan, indicating confidence in its financial position and future prospects [1] Group 1 - The company will repurchase 400,000 shares [1] - The total expenditure for the buyback is HKD 5.1349 million [1] - The buyback is scheduled for October 17, 2025 [1]

FF305 B. 贖回/購回股份 (擬註銷但截至期終結存日期尚未註銷) (註5及6) 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年10月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 ...

Group 1 - The Hong Kong stock market has seen a resurgence in activity, particularly among biopharmaceutical companies, with 19 companies successfully listed by October 10, 2025, surpassing the total of 12 for the entire year of 2024 [2] - The positive trend is attributed to new policies introduced by the Hong Kong Stock Exchange, including the "Science and Technology Enterprise Special Line" launched in May 2025, which supports early-stage biotech companies in listing [2][3] - In parallel, the A-share market has also shown new developments, with the China Securities Regulatory Commission announcing the restart of the fifth set of listing standards for unprofitable companies on the Sci-Tech Innovation Board [2] Group 2 - The 18A chapter listing rules introduced by the Hong Kong Stock Exchange in 2018 have provided crucial financing channels for biopharmaceutical companies by relaxing traditional profitability requirements and focusing on R&D progress [3][6] - As of May 2025, the 18A chapter has successfully facilitated the listing of 70 biopharmaceutical companies, demonstrating its effectiveness in addressing the financing challenges faced by these firms [3] - The 18C chapter is designed for specialized technology companies, allowing those in early commercialization stages to list without meeting traditional financial thresholds, thus broadening the scope of eligible companies [5][6] Group 3 - The listing conditions for the 18A chapter require biopharmaceutical companies to have at least one core product that has passed the concept stage and to focus on R&D with a minimum market capitalization of 1.5 billion HKD [4] - The 18C chapter differentiates between commercialized and non-commercialized companies, with specific market capitalization and R&D expenditure requirements [7] - The introduction of the third set of listing standards on the ChiNext board aims to support innovative companies, particularly those that integrate traditional industries with new technologies [28][30] Group 4 - The recent reforms in the Chinese capital market, including the reopening of the fifth set of standards for unprofitable companies on the Sci-Tech Innovation Board, provide critical financing opportunities for biopharmaceutical firms with core technologies [24][25] - The fifth set of standards has been expanded to include not only biopharmaceuticals but also other key emerging industries, enhancing the inclusivity of the listing process [25] - The ChiNext board's third set of standards eliminates profitability requirements, focusing instead on growth potential and technological value, thus allowing more innovative companies to access public markets [30][31] Group 5 - The choice of listing location is crucial for biopharmaceutical companies, with Hong Kong offering a more flexible environment for early-stage firms, while A-shares emphasize established technology and profitability [39][42] - Companies must consider various factors, including market conditions, regulatory requirements, and potential investor interest when deciding between Hong Kong and A-share listings [38][41] - The recent performance of biopharmaceutical companies listed in Hong Kong indicates a shift in market sentiment, with many stocks experiencing significant gains post-listing [42][43]

Core Viewpoint - The company, formerly known as Zijin Port Capital, has officially rebranded to "Haiyuan Capital," reflecting its commitment to long-term investment in hard technology and a global innovation perspective [1][3]. Group 1: Company Background and Achievements - Haiyuan Capital has been focused on hard technology investments for 11 years, managing a total scale of 7 billion yuan and successfully investing in over 120 innovative companies, with 8 of them having gone public [1][3]. - The firm has maintained a core investment philosophy of "invest early, invest small, invest well, and invest in hard technology," particularly in sectors such as semiconductors, artificial intelligence, new energy materials, and life sciences [1][3]. Group 2: Strategic Vision and Internationalization - The rebranding signifies a deeper understanding of the brand and an exploration of international strategies in hard technology investment, aiming to establish deep collaborations with top overseas institutions like MIT and Imperial College [3][5]. - The company plans to enhance its global resource and innovation network, focusing on technology collaboration and market integration between domestic and international enterprises [8][10]. Group 3: Investment Approach and Future Commitments - Haiyuan Capital will adhere to three main commitments: focusing on hard technology, upgrading global resources, and strengthening investment capabilities to achieve long-term win-win outcomes with limited partners and invested companies [8][10]. - The firm emphasizes a dual-core model of "investment + empowerment," providing comprehensive support from technology transformation to global expansion for its portfolio companies [6][8]. Group 4: Market Outlook and Innovation - The company recognizes the challenges and opportunities presented by the era of artificial intelligence and aims to continue discovering resilient entrepreneurs and innovative companies [12][14]. - Haiyuan Capital is optimistic about transformative forces in artificial intelligence, quantum computing, and life sciences, believing that innovation will shine through passion and persistence [14][16].